NovoCure Limited (FRA:038)
Germany · Delayed Price · Currency is EUR 10.73
+0.12 (1.13%)
At close: Nov 28, 2025
NovoCure Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited
| Country | Jersey |
| Founded | 2000 |
| Industry | Electromedical and Electrotherapeutic Apparatus |
| Employees | 1,488 |
| CEO | Ashley Cordova |
Contact Details
Address: Neuhofstrasse 21 Baar, 6340 Switzerland | |
| Website | novocure.com |
Stock Details
| Ticker Symbol | 038 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Ashley Cordova | Chief Executive Officer |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Ingrid Goldberg | Head of Investor Relations |